Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jack U Flanagan

Showing results (21-30 of 64) with videos related to

Pageof 7
Sort By:
Plos One|September 1, 2012
Crystal structures of three classes of non-steroidal anti-inflammatory drugs in complex with aldo-keto reductase 1C3Jack U Flanagan, Yuliana Yosaatmadja, Rebecca M Teague, et al.
Bioorganic & Medicinal Chemistry|November 19, 2016
Evaluation of known and novel inhibitors of Orai1-mediated store operated Ca<sup>2+</sup> entry in MDA-MB-231 breast cancer cells using a Fluorescence Imaging Plate Reader assayIman Azimi, Jack U Flanagan, Ralph J Stevenson, et al.
Bioorganic & Medicinal Chemistry|May 13, 2011
SAR studies of 4-pyridyl heterocyclic anilines that selectively induce autophagic cell death in von Hippel-Lindau-deficient renal cell carcinoma cellsMuriel Bonnet, Jack U Flanagan, Denise A Chan, et al.
The Biochemical Journal|December 17, 2002
Role of conserved Asp293 of cytochrome P450 2C9 in substrate recognition and catalytic activityJack U Flanagan, Lesley A McLaughlin, Mark J I Paine, et al.
Pharmaceuticals (Basel, Switzerland)|September 23, 2022
Evaluation of Novel Inhibitors of Tryptophan Dioxygenases for Enzyme and Species Selectivity Using Engineered Tumour Cell Lines Expressing Either Murine or Human IDO1 or TDO2Sofian M Tijono, Brian D Palmer, Petr Tomek, et al.
Clinical Science (London, England : 1979)|December 7, 2011
DMXAA (Vadimezan, ASA404) is a multi-kinase inhibitor targeting VEGFR2 in particularChristina M Buchanan, Jen-Hsing Shih, Jonathan W Astin, et al.
Journal of Medicinal Chemistry|August 6, 2010
Development and characterization of new inhibitors of the human and mouse hematopoietic prostaglandin D(2) synthasesAngelika N Christ, Larisa Labzin, Gregory T Bourne, et al.
Analytical and Bioanalytical Chemistry|January 15, 2013
Formation of an N-formylkynurenine-derived fluorophore and its use for measuring indoleamine 2,3-dioxygenase 1 activityPetr Tomek, Brian D Palmer, Jack U Flanagan, et al.
Journal of Structural Biology|November 3, 2015
Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealedYuliana Yosaatmadja, Shevan Silva, James M Dickson, et al.
The Journal of Biological Chemistry|November 26, 2002
Residues glutamate 216 and aspartate 301 are key determinants of substrate specificity and product regioselectivity in cytochrome P450 2D6Mark J I Paine, Lesley A McLaughlin, Jack U Flanagan, et al.
Pageof 7

Showing results (21-30 of 64) with videos related to

Sort By:
Pageof 7
Plos One|September 1, 2012
Crystal structures of three classes of non-steroidal anti-inflammatory drugs in complex with aldo-keto reductase 1C3Jack U Flanagan, Yuliana Yosaatmadja, Rebecca M Teague, et al.
Bioorganic & Medicinal Chemistry|November 19, 2016
Evaluation of known and novel inhibitors of Orai1-mediated store operated Ca<sup>2+</sup> entry in MDA-MB-231 breast cancer cells using a Fluorescence Imaging Plate Reader assayIman Azimi, Jack U Flanagan, Ralph J Stevenson, et al.
Bioorganic & Medicinal Chemistry|May 13, 2011
SAR studies of 4-pyridyl heterocyclic anilines that selectively induce autophagic cell death in von Hippel-Lindau-deficient renal cell carcinoma cellsMuriel Bonnet, Jack U Flanagan, Denise A Chan, et al.
The Biochemical Journal|December 17, 2002
Role of conserved Asp293 of cytochrome P450 2C9 in substrate recognition and catalytic activityJack U Flanagan, Lesley A McLaughlin, Mark J I Paine, et al.
Pharmaceuticals (Basel, Switzerland)|September 23, 2022
Evaluation of Novel Inhibitors of Tryptophan Dioxygenases for Enzyme and Species Selectivity Using Engineered Tumour Cell Lines Expressing Either Murine or Human IDO1 or TDO2Sofian M Tijono, Brian D Palmer, Petr Tomek, et al.
Clinical Science (London, England : 1979)|December 7, 2011
DMXAA (Vadimezan, ASA404) is a multi-kinase inhibitor targeting VEGFR2 in particularChristina M Buchanan, Jen-Hsing Shih, Jonathan W Astin, et al.
Journal of Medicinal Chemistry|August 6, 2010
Development and characterization of new inhibitors of the human and mouse hematopoietic prostaglandin D(2) synthasesAngelika N Christ, Larisa Labzin, Gregory T Bourne, et al.
Analytical and Bioanalytical Chemistry|January 15, 2013
Formation of an N-formylkynurenine-derived fluorophore and its use for measuring indoleamine 2,3-dioxygenase 1 activityPetr Tomek, Brian D Palmer, Jack U Flanagan, et al.
Journal of Structural Biology|November 3, 2015
Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealedYuliana Yosaatmadja, Shevan Silva, James M Dickson, et al.
The Journal of Biological Chemistry|November 26, 2002
Residues glutamate 216 and aspartate 301 are key determinants of substrate specificity and product regioselectivity in cytochrome P450 2D6Mark J I Paine, Lesley A McLaughlin, Jack U Flanagan, et al.
Pageof 7